Retraction: Mesenchymal Stromal Cells for Tissue-Engineered Tissue and Organ Replacements
Transplant International Editorial Office*A Retraction of the Review Article
Mesenchymal Stromal Cells for Tissue-Engineered Tissue and Organ Replacements
by Baiguera S, Jungebluth P, Mazzanti B, Macchiarini P. (2012). Transpl. Int. 2012; 25: 369-82. doi: 10.1111/j.1432-2277.2011.01426.x
Transplant International published in 2012 a review paper [1], in which another article from the same authors was cited [2]. This article had been published in the Lancet in 2008 and was very recently retracted for demonstrated falsification [3]. The falsification had been confirmed in a decision by the Swedish National Board for Assessment of Research Misconduct [4].
Briefly, the paper retracted by the Lancet described the allegedly successful transplantation of a tissue-engineered tracheal segment, reporting that “the graft immediately provided the recipient with a functional airway, improved her quality of life, and had a normal appearance and mechanical properties at 4 months” [2]. The conclusions of the investigation by the Swedish National Board for Assessment of Research Misconduct found that this statement constituted falsification [4].
The review article [1] was accepted and published in Transplant International based on its perceived quality and the supposed merits of the authors’ work. In this review, the authors stated that “(tissue engineering) has already provided functional tissue and organ human replacement” (sic), citing to support this point the retracted Lancet article [2] that they knew contained falsified data.
We are therefore retracting this review article.
Thierry Berney.
Transplant International editor-in-chief.
References
1. Baiguera, S, Jungebluth, P, Mazzanti, B, and Macchiarini, P. Mesenchymal Stromal Cells for Tissue-Engineered Tissue and Organ Replacements. Transpl Int (2012) 25:369–82. doi:10.1111/j.1432-2277.2011.01426.x
2. Macchiarini, P, Jungebluth, P, Go, T, Asnaghi, MA, Rees, LE, Cogan, TA, et al. Clinical Transplantation of a Tissue-Engineered Airway. Lancet (2008) 372:2023–30. doi:10.1016/S0140-6736(08)61598-6
3. The Editors of The Lancet. Retraction: Clinical Transplantation of a Tissue-Engineered Airway. Lancet (2023) 402:1510. doi:10.1016/S0140-6736(23)02341-3
4. Swedish National Board for Assessment of Research Misconduct. Decision Regarding Research Misconduct. Ref 3.2-22/0092 (2023). Available at: https://npof.se/wp-content/uploads/2023/10/Decision-in-case-3.2-22-0092_web.pdf (Accessed December 15, 2023).
Citation: Transplant International Editorial Office (2024) Retraction: Mesenchymal Stromal Cells for Tissue-Engineered Tissue and Organ Replacements. Transpl Int 37:12843. doi: 10.3389/ti.2024.12843
Received: 13 February 2024; Accepted: 23 February 2024;
Published: 05 March 2024.
Approved by:
Thierry Berney, University of Geneva, SwitzerlandCopyright © 2024 Transplant International Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Transplant International Editorial Office, tieditorialoffice@frontierspartnerships.org
